M. Litchman

发表

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

D. Porter, B. Levine, C. June, 2014 .

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

S. Grupp, D. Porter, B. Levine, 2013 .

Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).

R. Advani, P. Greenberg, B. Sikic, 1999, Blood.

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

D. Teachey, D. Porter, B. Levine, 2013 .

Phase I S tudy o f P aclitaxel i n C ombination W ith a Multidrug R esistance M odulator, P SC 8 33 ( Valspodar), i n Refractory M alignancies

P. Fracasso, E. Zuhowski, M. Egorin, 2000 .

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

T. Grogan, W. Dalton, R. Dorr, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

J. Chang, R. Marcus, R. Powles, 2001, Leukemia.

Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).

R. Advani, P. Greenberg, B. Sikic, 1999, Advances in experimental medicine and biology.

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

R. Advani, P. Greenberg, B. Sikic, 1999 .

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.

R. Advani, B. Sikic, G. Fisher, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.

A. Oza, E. Warner, M. Moore, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

P. Westervelt, P. Fracasso, E. Zuhowski, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

meeting held in San Diego, CA, December 1997. 833 (Valspodar) : Presented in part at the American Society of Hematology Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With

P. Greenberg, M. Tallman, E. Paietta, 2013 .

Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With

R. Advani, P. Greenberg, B. Sikic, 1999 .

Treatment of Poor Prognosis Acute Myelogenous Leukemia with PSC-833 and Mitoxantrone, Etoposide, Cytarabine

R. Advani, P. Greenberg, B. Sikic, 1998 .

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

D. Teachey, S. Grupp, D. Porter, 2014 .